Reforming Reimbursement for the US Food and Drug Administration’s Accelerated Approval Program to Support State Medicaid Programs
Bibliographic Data
| ID | 15808784 |
|---|---|
| Authors | Rachel E Sachs (0000-0002-0172-3572, Washington University in St. Louis, corresponding author), Julie M Donohue (0000-0003-2418-6017, University of Pittsburgh), Stacie B Dusetzina (0000-0002-3907-9196, Vanderbilt-Ingram Cancer Center) |
| Year | 2022 |
| Volume | 3 |
| Issue | 11 |
| Pages | e224115-e224115 |
| Publication date | 2022-11-18 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | JAMA Health Forum (JOURNAL) |
| Journal identifiers | ISSN: 2689-0186 • E-ISSN: 2689-0186 |
| Publisher | American Medical Association (PUBLISHER • US) |
| DOI | 10.1001/jamahealthforum.2022.4115 |
| PMID | 36399351 |
| OpenAlex | W4309492363 |
| Language | EN |
| References cited | 6 |
Policy makers may wish to consider options for reforming reimbursement for accelerated approval products in addition to reforms to the FDA's operation of the pathway. Policy reform proposals can provide a range of options to evaluate trade-offs of access and pricing
Administration (probate law · Business · Drug · Food and drug administration · Health care · Medicaid · Political science · Reimbursement · Risk analysis (engineering · State (computer science · Computer Science · Health and Medical Research Impacts · Health Systems, Economic Evaluations, Quality of Life · Healthcare cost, quality, practices · Law · Medicine · Pharmacology
| Highly cited | No |
|---|